1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 2: 
Characteristics of endovascular treatment
All Patients (n = 44)IV Tirofiban (n = 25)IA Tirofiban (n = 19)P Value
First-line endovascular technique (No. %)<.001
 ADAPT17 (38.6%)15 (60.0%)2 (10.5%)
 SR alone4 (9.1%)4 (16.0%)0 (0%)
 SR plus distal aspiration18 (40.9%)6 (24.0%)12 (63.2%)
 SAIL technique with tirofiban5 (11.4%)0 (0%)5 (26.3%)
 Angioplasty/stent placement0 (0%)0 (0%)0 (0%)
No. of passes before SAIL (median, IQR)3 (2−4)4 (2−5)3 (1−3).026
Reason for SAIL with tirofiban (No. %)<.001
 Incomplete reperfusion (eTICI 0–2a)11 (25.0%)0 (0%)11 (57.9%)
 Trend to re-occlusion16 (36.4%)14 (87.5%)2 (12.5%)
 Underlying primary or residual stenosis13 (29.5%)8 (32.0%)5 (26.3%)
Subocclusive thrombus4 (9.1%)3 (12.0%)1 (5.3%)
eTICI ≥2b after conventional MT (No. %)8 (18.2%)4 (16.0%)4 (21.1%).667
eTICI ≥2b after SAIL with tirofiban (No. %)35 (79.5%)20 (80.0%)15 (78.9%).932
Significant residual stenosis (>50%) after successful SAIL (No. %)16/35 (45.7%)11/20 (55.0%)5/15 (33.3%).203
Intracranial angioplasty and/or stent placement after tirofiban (No. %)15 (34.1%)11 (44%)4 (21.0%).112
 Angioplasty9 (20.5%)7 (28.0%)2 (10.5%)
 Stent placement6 (13.6%)4 (16.0%)2 (10.5%)
Final eTICI ≥2b (No. %)39 (88.6%)24 (96.0%)15 (78.9%).077
Groin-to-reperfusion time (mean) (min)100 (SD, 32)111 (SD, 34)87 (SD, 24).009
Procedural complications (No. %).587
 Vasospasm target vessel3 (6.8%)2 (8.0%)1 (5.3%)
 Dissection target vessel1 (2.3%)1 (4.0%)0 (0%)
 Perforation1 (2.3%)0 (0%)1 (5.3%)
 Dissection/perforation at tirofiban bailout0 (0%)0 (0%)0 (0%)
 Distal embolism5 (11.4%)2 (8.0%)3 (15.8%)
 New territory embolism0 (0%)0 (0%)0 (0%)
 In-stent thrombosis0 (0%)0 (0%)0 (0%)
 ICA dissection/vasospasm0 (0%)0 (0%)0 (0%)
  • Note:—ADAPT indicates A Direct Aspiration First Pass Technique.